Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 3
2014 1
2015 4
2016 1
2017 4
2019 3
2020 4
2021 7
2022 9
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
[POEMS-syndrome].
Arkhipov IE, Vergunova IY, Malkova NA, Korobko DS. Arkhipov IE, et al. Among authors: korobko ds. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(7. Vyp. 2):15-21. doi: 10.17116/jnevro202312307215. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37560829 Russian.
CLIPPERS: Multiparametric and quantitative MRI features.
Korostyshevskaya AM, Stankevich JA, Vasilkiv LM, Bogomyakova OB, Korobko DS, Gornostaeva AM, Tulupov AА. Korostyshevskaya AM, et al. Among authors: korobko ds. Radiol Case Rep. 2022 Nov 17;18(1):368-376. doi: 10.1016/j.radcr.2022.10.043. eCollection 2023 Jan. Radiol Case Rep. 2022. PMID: 36411846 Free PMC article.
[Susac syndrome, review and clinical case].
Vergunova IY, Malkova NA, Korobko DS. Vergunova IY, et al. Among authors: korobko ds. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):52-57. doi: 10.17116/jnevro20191192252. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31156242 Review. Russian.
[Approaches to vaccine prevention in multiple sclerosis].
Kasatkin DS, Korobko DS, Matson MD, Lendoeva DV, Ivanova SP. Kasatkin DS, et al. Among authors: korobko ds. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(9):29-36. doi: 10.17116/jnevro202212209129. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 36168685 Russian.
42 results